NNUH - Our vision Norfolk and Norwich University Hospitals
Print this page

University of East Anglia

our research partners hotspotThe University of East Anglia is the number one university in the UK for student satisfaction in the 2013 Times Higher Education Student Experience Survey.

University of East Anglia is ranked in the top 1% of Higher Education institutions in the world and is a leading member of the Norwich Research Park, one of Europe’s biggest concentrations of researchers in the fields of environment, health and plant science.

In 2002, in partnership with the University of East Anglia, the Trust achieved teaching hospital status with the opening of the new Norwich Medical School. In 2003/4 the Trust made an investment of £3m to establish a joint Clinical Research and Trials Unit.

This investment by the Trust in joint clinical and health sciences research has continued. In 2009 the Trust Board approved a joint research strategy with University of East Anglia in which both parties committed significant investment to expand the number of clinical academic posts in Norwich and encourage greater involvement of the consultant staff in clinical research. This was supplemented in 2011 with the appointment of a Joint Director of Research and Development and in 2012 with the establishment of a Joint Research Office.

Other recent specific investments by the Trust in partnership with University of East Anglia to support research are:

  • The recent purchase of a new 3T MRI Scanner for research – this is currently one of the most advanced imaging magnets in the UK and one of the first four of its kind in the world.  A new professor of MR physics has also been appointed in order to maximise its effectiveness.
  • The Bob Champion Research and Education Building opened on the Norwich Research Park in February 2015. The £19m building is managed by UEA in partnership with the Norfolk & Norwich University Hospital and provides state of the art laboratories for our research teams to undertake world class research into prostate cancer, antibiotic resistance disease, musculo-skeletal disease and gastrointestinal diseases.